Institute of Immunology and Immunotherapy Immunology is at the forefront of medical research and we are among the leaders of this exciting, fast-evolving field.
COVID-19 News New study finds strong immune response following COVID-19 vaccination A new study carried out in collaboration with the University of Birmingham with support from the UK Coronavirus Immunology Consortium has found that 99% of people generate a robust immune response against COVID-19 after just one dose of the Pfizer vaccine.
COVID-19 New gene therapy innovation centre to advance scientific discoveries into life-changing treatments
Posted 22 October 2021 A third of leukaemia patients do not generate any antibody response to two doses of COVID-19 vaccination, study shows A University of Birmingham-led study has shown that a third of patients with the most common type of leukaemia fail to generate any measurable antibody response following two doses of COVID-19 vaccination.
Posted 11 October 2021 Milestone moment for the region's life science sector as construction on No. 1 Birmingham Health Innovation Campus gets underway Construction of No.1 Birmingham Health Innovation Campus (BHIC) in Selly Oak is underway, marking a major milestone for the region's rapidly growing life sciences sector.
Posted 16 September 2021 Research provides new insight into fundamental workings of the immune system in response to therapy to treat skin cancer New research suggests that skin cancer patients could have a better prognosis if their T cells send messages from five specific genes in their immune response to drugs given to treat the disease.
Posted 14 September 2021 University of Birmingham scientists in new COVID-19 study University of Birmingham researchers are part of a new study seeking to understand why some people become infected with COVID-19 after vaccination or prior infection while others do not.
Posted 29 July 2021 Birmingham cancer project enters Immuno-oncology Alliance Birmingham researchers partnered with Cancer Research UK in one of the first target identification projects for the Immuno-oncology Alliance, which translates discovery science into new therapeutics for cancer patients.
Posted 23 July 2021 Longer interval between the first and second Pfizer vaccine boosts antibody levels and 'helper' T cells A new study carried out in collaboration with the University of Birmingham shows both short and long dosing schedules of the Pfizer COVID-19 vaccine generate strong antibody and T cell immune responses.